Complement cascade

Complement cascade
English text of 'Image:Complement pathway.png' by DO11.10 German translation of · Public domain · source
Name	Complement cascade
Organism	Homo sapiens
Discovery	Paul Ehrlich; Jules Bordet
Components	C3 (complement); C5 (complement); Factor B (complement); Factor D (adipsin); Properdin

Complement cascade is a proteolytic cascade in the innate immune system that amplifies responses to pathogens, links innate and adaptive immunity, and mediates clearance of immune complexes. Discovered through early work by Paul Ehrlich and Jules Bordet, the cascade involves sequential activation of plasma proteins that generate opsonins, anaphylatoxins, and the membrane attack complex. It intersects with pathways activated during infection, inflammation, and tissue injury and is implicated in many clinical conditions managed by institutions such as National Institutes of Health and World Health Organization.

Overview

The cascade operates as a series of zymogen activations centered on key proteins including C3 (complement), C4 (complement), and C5 (complement), producing effectors such as C3b and C5a. Historically, studies at laboratories associated with Rockefeller University and Pasteur Institute defined functional properties like lytic activity and hemolysis, shaping modern immunology curricula at Harvard Medical School and Johns Hopkins University. Clinical translation has been driven by pharmaceutical research from companies like Alexion Pharmaceuticals and regulatory guidance from European Medicines Agency.

Pathways and Activation

Activation occurs via three principal arms: the classical pathway initiated by antigen–antibody complexes involving IgM and IgG (immunoglobulin G), the lectin pathway triggered by pattern recognition molecules such as Mannose-binding lectin and ficolin-2, and the alternative pathway that amplifies activation via spontaneous hydrolysis and factors like Factor B (complement) and Properdin. Cross-talk with adaptive elements includes interactions with receptors on B cell and T cell populations characterized in research at Cold Spring Harbor Laboratory and Salk Institute. Complement activation is studied in models ranging from work at Max Planck Institute to clinical cohorts at Mayo Clinic.

Components and Molecular Mechanisms

Central components encompass serine proteases such as C1s and C1r within the C1 complex, convertases like C3 convertase and C5 convertase, and terminal components C6 (complement) through C9 (complement) that assemble the membrane attack complex. Mechanistic elucidation has relied on structural biology performed at facilities like European Molecular Biology Laboratory and Argonne National Laboratory, while genetics elucidated roles of complement regulators via studies at University of Cambridge and University of Oxford. Complement receptors including CR1 and CR3 mediate opsonization and interact with immune cells described in research from Stanford University School of Medicine.

Regulation and Inhibition

Homeostasis is maintained by membrane-bound and fluid-phase regulators such as Decay-accelerating factor (DAF), Factor H (complement control protein), and CD59, which prevent autologous tissue damage; dysregulation underlies pathologies investigated at Imperial College London and University College London. Therapeutic inhibition has been advanced by monoclonal antibodies like eculizumab developed by Alexion Pharmaceuticals and small molecules evaluated in trials overseen by Food and Drug Administration and European Medicines Agency. Complement evasion strategies are exploited by pathogens studied at Centers for Disease Control and Prevention and vaccine research at Gavi, the Vaccine Alliance.

Physiological Roles and Clinical Significance

Physiologically, the cascade contributes to host defense against bacteria such as Neisseria meningitidis and clearance of apoptotic cells; it modulates processes in organs studied at Massachusetts General Hospital and Cleveland Clinic. Clinically, complement involvement is central to diseases including atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, and autoimmune conditions researched at Mayo Clinic and treated in specialty centers like Johns Hopkins Hospital. Complement-targeted therapies and diagnostics feature in clinical guidelines from American College of Rheumatology and interventional studies coordinated by National Institutes of Health networks.

Laboratory Testing and Diagnostic Use

Diagnostic evaluation uses assays measuring components and activity: hemolytic assays (CH50, AH50), ELISA quantification of individual proteins such as C3 (complement) and C4 (complement), and functional testing performed in clinical laboratories accredited by College of American Pathologists and regulated under frameworks from Clinical Laboratory Improvement Amendments. Interpretation informs management of immune deficiency, complement-mediated nephropathies, and transplant immunology as practiced at centers like Mayo Clinic and Cedars-Sinai Medical Center. Emerging diagnostics include mass spectrometry approaches developed in collaborations between University of California, San Diego and industry partners.

Category:Immunology Category:Human physiology